Nitro Oxide And Ovarian Cancer
The precise mechanisms by which the host defense to malignant tumors is mediated in vivo is not known. It is now believed that cancer cells themselves may trigger an immune response and this may limit the progression of the tumor. It is also possible to induce non specific resistance to cancer cells therapeutically. Intraperitoneal (i.p.) inoculation of Cornebacterium parvum, which increases nonspecific resistance to murine ovarian teratocarcinoma (MOT) cells can cure mice bearing these tumor cells . Similarly, i.p. administration of Cornebacterium parvum to women  was at least partially effective in the treatment of minimal residual ovarian cancer in women. However, the mechanism by which this occurs is not known. Similarly, bacillus Calmette-Guerin (BCG) also appears to be an immununostimulant. When cultured in vitro, peritoneal macrophages obtained from mice previously inoculated with BCG release NO, which is cytostatic or cytolytic for tumor cells ,. This in vitro cytostatic and/or cytolytic activity is also observed after activation of the macrophages by cytokines ,. Interferon γ (INFγ) is important for the priming of macrophages, and tumor necrosis factor α (TNFα) or some other cytokine or bacterial lipopolysaccharide (LPS) is necessary for full induction of activated macrophage cytotoxicity ,. However, the role of NO in mediating tumoricidal activity in vivo and the mechanism by which this occurs is not exactly known. We therefore evaluated the role of NO in mediating both tumoricidal activity in vivo and the mechanism by which this occurs.
KeywordsOvarian Cancer Host Resistance Ovarian Cancer Cell Line Human Ovarian Cancer OVCAR Cell
Unable to display preview. Download preview PDF.
- 15.van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, Kerckhaert JA, Schreinemachers LM, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruijne FM, Ruitenberg EJ (1989) Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guerin. Cancer Immunol Immunother 28: 287–295PubMedCrossRefGoogle Scholar
- 16.Alberts DS, Mason-Liddil N, O’Toole RV, Abbott TM, Kronmal R, Hilgers RD, Surwit EA, Eyre HJ, Baker LH (1989) Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol 32: 16–21PubMedCrossRefGoogle Scholar